Allergy Therapeutics - Invalidation of Birch MATA MPL phase III results
- Technical issues with the endpoint measurements invalidated B301 trial
- New pivotal Phase III Study with Birch MATA MPL to be conducted within TAV time frame
Further to the announcement on
The Group's confidence in its short course immunotherapies remains unchanged and lessons learned from the Birch B301 field study have already been introduced for future studies including the Grass MATA MPL programme to be conducted simultaneously in the US and
"We look forward to progressing our portfolio of unique allergy vaccines and helping the millions of patients affected by allergy via our phase III studies with Birch MATA MPL as well as Grass MATA MPL and our upcoming first in human peanut trial."
This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
For further information, please contact:
+44 (0)1903 845 820
Nick Wykeman, Chief Financial Officer
+44 (0) 20 7886 2500
Consilium Strategic Communications
+44 20 3709 5700
Stern Investor Relations, Inc.
+1 212 362 1200
Notes for editors:
Formed in 1999 out of
About Birch MATA MPL
Birch MATA MPL is a subcutaneous allergen-specific immunotherapy designed to treat the cause of allergic rhinitis not just mask the symptoms. It consists of a birch pollen allergoid combined with an adjuvant system comprised of microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL®).
Allergoids (natural allergens chemically modified to form allergoids) exhibit reduced allergenicity that improves tolerability and allows for delivery of higher doses. These allergoids are combined with an adjuvant system including depot adjuvant technology MCT to provide enhanced immune exposure and further improved tolerability and MPL® to enhance and direct the immune response. MPL is a toll-like receptor 4 (TLR4) agonist that has been extensively used in the Group's other allergy vaccines available on the market and in vaccines registered in the
This information is provided by RNS, the news service of the
Quick facts: Allergy Therapeutics PLC
Market Cap: £101.17 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE